The Globe and Mail3h
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
However, that is less true for large-cap stocks like Merck and Bristol-Myers. Still, it’s important to understand why ...
ENDPOINTS NEWS14h
Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug
Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...
ENDPOINTS NEWS17h
Mer­ck KGaA plans Chi­na sub­mis­sion af­ter late-stage win for tu­mor drug
Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...
pharmaphorum18h
Merck drug for rare tumour hits phase 3 target
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...